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Rationale: 1 
Eradication and suppression of Pseudomonas aeruginosa is a key priority in national guidelines for 2 
bronchiectasis, and is a major focus of drug development and clinical trials. An accurate estimation 3 
of the clinical impact of P. aeruginosa in bronchiectasis is, therefore, essential. 4 
Methods 5 
Data from 21 observational cohort studies comparing patients with P. aeruginosa colonisation to 6 
those without were pooled by random effects meta-analysis with data collected for key longitudinal 7 
clinical outcomes of mortality, hospital admissions, exacerbations and lung function decline along 8 
with cross sectional outcomes such as quality of life. 9 
Measurements and main results: 10 
Studies included 3683 patients. P. aeruginosa was associated with a highly significant and consistent 11 
increase in all markers of disease severity including mortality (odds ratio (OR) 2.95, 95% CI 1.98-4.40; 12 
p<0.0001), hospital admissions (OR 6.57, 95% CI 3.19-13.51; p<0.0001) and exacerbations (mean 13 
difference 0.97 per year, 95% CI 0.64-1.30; p<0.0001). Patients with P. aeruginosa also had worse 14 
quality of life using the St Georges Respiratory Questionnaire (mean difference 18.2 points, 95% CI 15 
14.7-21.8; p<0.0001). There were also large differences in lung function and radiological severity.  16 
Definitions of colonisation were inconsistent but findings were robust irrespective of the definition 17 
used.  18 
Conclusion: P. aeruginosa is associated with an approximate 3-fold increased risk of death and an 19 
increase in hospital admissions and exacerbations in adult bronchiectasis.   20 
 21 
 22 
Primary source of funding: European Bronchiectasis Network (EMBARC) 23 
  24 
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Introduction 25 
Bronchiectasis is a chronic inflammatory lung disease characterised by recurrent cough, sputum 26 
production and recurrent respiratory tract infections.(1) Failure of the mucociliary escalator and 27 
innate antimicrobial defences leads to chronic bacterial colonisation of the airways.(2) Bacteria 28 
provoke an inflammatory response that can further drive airways inflammation and airway 29 
structural damage leading to the well described “vicious cycle” of bronchiectasis.(2,3) 30 
While the majority of patients with bronchiectasis may be colonised with organisms that are upper 31 
airway commensals such as Haemophilus influenzae and Streptococcus pneumoniae, a proportion of 32 
patients become colonised with the opportunistic pathogen Pseudomonas aeruginosa.(4-6)  33 
In cystic fibrosis (CF) bronchiectasis, it is well established that P. aeruginosa colonisation leads to a 34 
more rapid deterioration in lung function and earlier mortality.(7) Consequently, P. aeruginosa 35 
eradication is standard care in European CF centres.(8,9)  The capability of P. aeruginosa to form 36 
biofilms provide it with physical and chemical protection from the immune system and reduces its 37 
exposure to systemically delivered antibiotics.(10,11) P. aeruginosa has the ability to rapidly adapt to 38 
chronic infection in the lung and readily develops antimicrobial resistance. Management of P. 39 
aeruginosa therefore represents a significant clinical challenge.  40 
In bronchiectasis, conflicting data have been published on the independent contribution of P. 41 
aeruginosa to long term prognosis and there remains a question of whether P. aeruginosa drives 42 
disease progression or is simply a marker of existing severe disease.(12,13) Determining the 43 
importance of P. aeruginosa to bronchiectasis morbidity and mortality is important, as there are few 44 
evidence based treatments for bronchiectasis.(14) Current therapeutic development is heavily 45 
influenced by CF and is therefore largely targeted towards treatment of P. aeruginosa 46 
infection.(15,16) Therefore from clinical, drug development and regulatory perspectives it is 47 
important to have a comprehensive understanding of the impact of P. aeruginosa on outcomes in 48 
bronchiectasis. 49 
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We therefore undertook a systematic review to determine whether colonisation with P. aeruginosa 50 
influences future prognosis and/or is associated with cross-sectional features of severity. 51 
  52 
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METHODS 53 
The present study was a systematic review and meta-analysis conducted and reported according to 54 
MOOSE (meta-analysis of observational studies in epidemiology) guidelines.(17) 55 
Search Criteria 56 
The study was based on a search of the PUBMED database for articles evaluating the prognostic 57 
impact of colonisation with P. aeruginosa. The following search strategy was used: ("Pseudomonas" 58 
OR "aeruginosa") AND ("bronchiectasis") followed by (“prognosis” or “mortality”) and 59 
(“bronchiectasis”). The search included articles published between January 1980 and January 2015. 60 
No language criteria were applied. Full articles of potentially appropriate abstracts were reviewed. 61 
Only peer reviewed data were included. Conference abstracts were excluded. The search was 62 
repeated in EMBASE and Web of Science to obtain any articles missed by the initial search. The 63 
search strategy was supplemented by reviewing of the reference lists, bibliographies including the 64 
British Thoracic Society guidelines and investigator files.  65 
 66 
Data extraction  67 
Non relevant studies were excluded based on review of the title and abstract. Article reviewing was 68 
performed independently by two investigators ((two out of SF, ,MM, AHL, SA and JC) who conducted 69 
data extraction and quality assessment from studies meeting the inclusion criteria. All investigators 70 
have experienced of meta-analysis and training in literature review. Any disagreement between 71 
investigators was resolved independently by a third investigator. Additional unpublished data were 72 
obtained from study authors where possible. Where data were presented only as medians, means 73 
with standard deviation were estimated according to the formula of Hozo et al.(18) 74 
 75 
 76 
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Study inclusion and exclusion criteria 77 
All studies were considered eligible if they fulfilled the following criteria: original publications; 78 
inclusion of a cohort of patients with computed tomography diagnosed bronchiectasis not due to 79 
cystic fibrosis; inclusion of patients with P. aeruginosa colonisation and a comparator population 80 
without P. aeruginosa colonisation;  reporting of one of the study outcomes which were determined 81 
a priori (described below).  82 
Definitions of P. aeruginosa colonisation were obtained from the source studies and were not pre-83 
specified.  84 
As the aim of this study was to compare P. aeruginosa colonised patients compared to non-85 
colonised patients, we excluded any studies which provided data only for a single population. We 86 
also excluded case reports; review articles, editorials and letters without original data. 87 
 88 
Study outcomes 89 
Primary analysis 90 
Our hypothesis was that P. aeruginosa colonisation would be associated with globally worse clinical 91 
outcome when compared to patients without P. aeruginosa colonisation. Outcomes were split into 92 
longitudinal clinical outcomes determined during follow-up, and cross-sectional outcomes. The 93 
primary longitudinal outcome was all-cause mortality. Secondary outcomes were: hospital 94 
admissions, exacerbation frequency, decline in forced expiratory volume in 1 second (FEV1) and the 95 
prognostic impact of P. aeruginosa eradication therapy. 96 
Cross sectional outcomes were: FEV1 % predicted, forced vital capacity (FVC), radiological 97 
involvement and quality of life (QoL). A descriptive analysis of the methods of defining P. aeruginosa 98 
colonisation in the literature was also considered a pre-specified secondary end-point.  99 
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Anticipating that studies would have different lengths of follow-up to determine survival, we pre-100 
specified that data could be pooled where equal follow-up was demonstrated between P. 101 
aeruginosa colonised and non-colonised patients.  102 
 103 
Quality assessments 104 
The quality of each study was independently assessed according to the criteria described by Hayden 105 
et al, which are widely used for assessing the quality of observational studies in meta-106 
analysis.(19,20) The agreement between the two reviewers (two of SF, AHL and JC) was measured 107 
using the kappa statistic. Publication bias was determined by visual inspection of funnel plots and 108 
Eggers test. 109 
 110 
Sensitivity analysis 111 
A priori we identified possible factors that may be major sources of bias and planned subanalyses for 112 
the follow; 1) Analysis according to different definitions of P. aeruginosa colonisation e.g single 113 
isolate versus multiple isolatins; 2) Comparison of P. aeruginosa vs H. influenzae colonised patients 114 
compared to comparisons of P. aeruginosa colonised vs non-colonised patients; 3) Data derived 115 
from high quality and prospective studies.  116 
 117 
Statistical analysis 118 
The primary outcome of the relationship between P. aeruginosa colonisation and mortality was 119 
displayed as odds ratios (OR) with 95% confidence intervals (95% CI). ORs were pooled using a 120 
Mantel-Haenszel random effects model. The same analysis was used for hospital admissions.  121 
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Continuous variables such as quality of life, lobar involvement, pulmonary function tests and 122 
exacerbations were compared by pooling mean differences by the inverse of their variance. As 123 
above, random effects meta-analysis was used due to expected heterogeneity between studies. To 124 
analyse for possible effect modifiers, such as study quality or definitions of colonisation, we 125 
compared OR’s using interaction testing as described.  126 
Statistical heterogeneity was assessed using the Cochran Q (χ2) test and the Higgins I2 tests. For the 127 
Cochran Q test, p<0.1 was considered to represent significant heterogeneity. For the Higgins test, I2 128 
<25% indicated low heterogeneity, 25–50% moderate and >50% severe heterogeneity. Analyses 129 
were conducted using Review Manager 5 (Cochrane Collaboration) and SPSS version 21 for windows 130 
(Chicago, IL, USA).  131 
 132 
 133 
 134 
 135 
RESULTS 136 
 137 
The results of the literature review are shown in figure 1. The majority of studies were rejected 138 
because they did not deal specifically with patients with bronchiectasis not due to CF or did not 139 
evaluate severity or outcomes. Of 55 articles selected as relevant, 21 studies had valid data for 140 
inclusion and were pooled in the meta-analysis.(6,12,13,21-36) One study contained data for 5 141 
cohorts and each cohort was considered separately for the purposes of this analysis on the basis that 142 
they were independent cohorts (total 25 cohorts).(24)  143 
 144 
 145 
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Characteristics of the 21 included studies are shown in table 1. 10 studies were from the UK 146 
(12,21,23,24,26,28,31,32) and overall 16 cohorts were from Europe. There were no cohorts from 147 
North America.  148 
 149 
Definitions of chronic P. aeruginosa colonisation were highly heterogeneous. The most frequent 150 
definition used was 2 positive cultures at least 3 months apart over 12 months. 5 studies reported 151 
patients with a single positive culture as “colonised”. In all, 8 different methods of defining P. 152 
aeruginosa colonisation were identified in addition to 3 studies where the definition was not stated. 153 
According to the quality assessment, 6 studies were rated as high quality, 8 as intermediate, and 7 as 154 
low quality (Kappa 0.73). None of the analyses showed evidence of publication bias.  155 
 156 
The total number of patients studied was 3683 with a rate of P. aeruginosa colonisation (according 157 
to study definitions) of 21.4%. Comparator populations were almost universally mixed populations 158 
of bronchiectasis not colonised with P. aeruginosa.  159 
 160 
Impact of P. aeruginosa on longitudinal outcomes 161 
Primary outcome: All-cause Mortality 162 
Mortality was available as an outcome in 8 cohorts (24-27) of which 5 cohorts were derived from a 163 
single study (24). Follow-up duration ranged from 1 year to 14 years. Mortality for patients with P. 164 
aeruginosa ranged from 7.7% at 1 year, 13.6% at 2 years to 30-50% at 5 years. Corresponding 165 
mortality rates for patients without P. aeruginosa were 0% at 1 year, 7% at 2 years and 9-15% at 5 166 
years. All studies showed a higher risk of mortality associated with P. aeruginosa colonisation. The 167 
pooled OR for mortality was 2.95 (95% CI 1.98-4.40; p<0.0001). Heterogeneity tests were not 168 
statistically significant. This is shown in figure 2. 169 
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Sub-analyses confirmed this association in high quality studies (OR 3.64, 95% CI 1.75-7.55; p=0.0005, 170 
n=1433), prospective studies and excluding studies with <3 (OR 2.82, 95% CI 1.94-4.11; p<0.0001, 171 
n=1994) and >6 years follow-up (OR 3.14, 95% CI 1.83-5.33; p<0.0001, n=1894).  172 
 173 
Hospital admissions 174 
This analysis included 7 cohorts with 1628 participants (23,24,29). Hospital admission rates for 175 
patients with P. aeruginosa varied from 41% at 1 year to 75% at 4 years. Corresponding hospital 176 
admission rates in patients without P. aeruginosa were 15% at 1 year and 28.5% at 4 years. P. 177 
aeruginosa was associated with a marked increase in the risk of hospital admissions – pooled OR 178 
6.57 (95% CI 3.19-13.51; p<0.0001). There was significant heterogeneity which was not resolved on 179 
limiting studies by quality, prospective design or length of follow-up. Insufficient data was available 180 
to evaluate additional impacts such as length of hospital stay or economic impacts of hospitalisation. 181 
Data are shown in figure 3.  182 
 183 
 184 
Exacerbations per year 185 
All available data were presented as mean exacerbations per patient per year. The 9 cohorts which 186 
recorded this information gave a pooled increased frequency of just under 1 exacerbation per 187 
patient per year – mean difference 0.97 (95%CI 0.64-1.30; p<0.0001) with no significant 188 
heterogeneity.(6,23,24,29,30) This is shown in figure 4. No significant differences in effect were 189 
observed in high quality studies, prospective studies or in sub-analyses based on the definition of P. 190 
aeruginosa.  191 
 192 
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Lung function decline 193 
There were limited data available on lung function decline. One study reported lower lung function 194 
in PA colonised patients but no differences in long term lung function decline.(13) Another study 195 
reported a mean decline of 52ml per year in P. aeruginosa patients(12) with a further study 196 
reporting a mean decline of 123ml per year.(38) The available data included only 41 patients with P. 197 
aeruginosa colonisation. Consequently no attempt was made to pool the data.  198 
 199 
Pseudomonas eradication treatment 200 
No randomised studies of P. aeruginosa eradication treatment were identified. A non-randomised 201 
observational study (n=30) reported an initial eradication success rate of 80%, and 43% after a 202 
median of 6 months.(39) This was associated with a reduction in exacerbations from 3.93 per year to 203 
2.03 per year. No control population was available for comparison with no data on the spontaneous 204 
clearance rate that would have occurred without treatment. 205 
 206 
 207 
Cross sectional association between P. aeruginosa and markers of severe disease 208 
Patient characteristics 209 
In cross-sectional studies we observed that patients with P. aeruginosa infection were on average 3 210 
years older than non-colonised patients (mean difference 3.1 years, 95% CI 0.9-5.4,p=0.007, I2=48%). 211 
Interestingly there was a statistically significant association between male gender and P. aeruginosa 212 
colonisation, OR 1.39 95% CI 1.09- 1.75, p=0.009, I2=0%.  213 
Quality of life 214 
The only data that were available for QoL used the St.Georges Respiratory Questionnaire (SGRQ). 215 
The SGRQ is a validated questionnaire in patients with bronchiectasis that has been widely used with 216 
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an accepted increment of 4 points demonstrating clinical significance.(37)  4 studies reported data 217 
for SGRQ, with a mean difference of 18.2 points (95% CI 14.7-21.8; p<0.0001, n=1041).(22,24,28) 218 
There was no heterogeneity between studies (I2=0%). No data were available for other 219 
questionnaires, including the QoL-Bronchiectasis questionnaire. 220 
 221 
Lung Function- FEV1 and FVC 222 
As expected, patients with P. aeruginosa colonisation had worse cross-sectional lung function 223 
compared to patients without P. aeruginosa. 17 studies reported valid data for FEV1 with all showing 224 
worse lung function in the P. aeruginosa group ranging from -1.4% to -29%. 225 
(6,12,13,21,22,24,28,29,30,31,33,34,36) The pooled mean difference was 15.0% (95% CI -18.7 to -226 
11.3; p<0.0001). There was significant heterogeneity but this was no longer statistically significant 227 
after excluding 1 study that defined P. aeruginosa presence by PCR.(6)  9 cohorts presented data for 228 
FVC with a pooled mean difference of -9.4% (95% CI -14.3 to -4.5%;p=0.005, n=1453). 229 
(12,24,28,29,33,34)  230 
 231 
Radiological severity 232 
Although multiple severity scoring systems have been utilised in bronchiectasis, the only variable 233 
which was studied in more than one study was the number of lobes involved on CT. This data were 234 
available in 9 cohorts.(24,29,30,32,34,35) The mean difference between P. aeruginosa colonised and 235 
non-colonised was 1.4 lobes (95% CI 0.93-1.86; p<0.0001). Nevertheless all studies reported worse 236 
radiological severity in P. aeruginosa colonised patients.  237 
Sensitivity analyses 238 
Limiting the analysis to only those studies that used the most robust definition of P. aeruginosa 239 
colonisation, requiring at least 2 positive sputum samples over a 12 month period, showed very 240 
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similar results to the primary analysis with ORs for mortality of 3.46, 95% CI 1.96-.6.08; p<0.0001;  241 
hospital admissions 7.22, 95% CI 2.88-18.09; p<0.0001 and exacerbations mean difference 0.87, 95% 242 
CI 0.59-1.15; p<0.0001 (p>0.5 when comparing odds ratios using interaction testing compared to the 243 
overall cohort). 244 
 245 
8 cohorts provided data that could be used to directly compare the outcomes of patients colonised 246 
with P. aeruginosa versus Haemophilus influenzae. The findings were highly consistent with the main 247 
analysis, with an increase in mortality associated with P. aeruginosa (OR 4.00, 95% CI 2.28-7.02; 248 
p<0.001), increased rate of hospital admissions (OR 6.75, 95% CI 3.98-11.45; p<0.001), increased 249 
exacerbations (mean difference 0.99 (95% CI 0.54-1.43; p<0.0001) and low FEV1 (mean difference -250 
11.4, 95% CI -14.8 to -7.9; p<0.0001).   251 
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DISCUSSION 252 
The management of bronchiectasis patients with P. aeruginosa colonisation is challenging and a 253 
large proportion of the current therapeutic development in bronchiectasis is focussed towards 254 
management of P. aeruginosa infection.(14-16) In particularly there are intensive efforts in the field 255 
of inhaled antibiotics to develop a licensed therapy for P. aeruginosa infection in 256 
bronchiectasis.(15,16) Therefore an accurate assessment of the prognostic impact of P. aeruginosa 257 
in bronchiectasis is important for clinicians, for drug developers and for regulators. This analysis 258 
provides a detailed insight into the impact that P. aeruginosa colonisation has on key clinical 259 
outcomes in bronchiectasis. In addition, P. aeruginosa colonisation was associated with multiple 260 
cross-sectional markers of disease severity. It can therefore be said that P. aeruginosa is both a 261 
marker of severe disease, and is associated with a worse long term prognosis. Bronchiectasis has 262 
historically been a neglected condition, described in the ERS white book as one of the most 263 
neglected diseases in respiratory medicine.(40) As a result, there have been few large cohort studies. 264 
The value of meta-analysis therefore is to combine the available data from existing small studies to 265 
give a more accurate estimate of the disease impact.  266 
The most striking finding within this analysis is the impact of P. aeruginosa on all-cause mortality. 267 
Our analysis identifies a 3-fold increase in the risk of death with P. aeruginosa colonisation. P. 268 
aeruginosa was also associated with a greatly increased the risk of hospital admissions and 269 
exacerbation frequency by a rate of 1 exacerbation per patient per year. This finding was robust 270 
regardless of the definition used and was consistent across all cohorts. These results strengthen the 271 
view that patients with P. aeruginosa require specific treatment to reduce the risk of long term 272 
morbidity and mortality and that P. aeruginosa colonisation status should play a key role in the 273 
assessment of disease severity.(14)  274 
The increased exacerbation frequency and hospital admissions demonstrates a measurable 275 
healthcare cost associated with P. aeruginosa colonisation. Each additional exacerbation results in 276 
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further antibiotic use with associated risks and side-effects as well as increased potential for the 277 
development of antimicrobial resistance. Exacerbations are associated with reduced productivity 278 
through absence from work and are associated with poorer QoL and potential lung function 279 
decline.(24,38,41) Hospital admissions may reflect more severe exacerbations or the development 280 
of resistance to oral antibiotic agents necessitating intravenous antibiotic therapy.(24) The ability of 281 
P. aeruginosa to develop antibiotic resistance is inevitably enhanced by repeated antibiotic 282 
exposure.(29) 283 
Our analyses of quality of life, lung function and radiological severity were cross-sectional and can 284 
therefore only be considered hypothesis generating in terms of the impact of P. aeruginosa on these 285 
outcomes over the long term. Nevertheless the impact on QoL demonstrated in this analysis is 286 
striking. The 18 point decrement in the SGRQ demonstrated in patients with P. aeruginosa 287 
colonisation reflects a dramatic worsening of QoL. Given our observation that patients with P. 288 
aeruginosa had reduced lung function and more widespread radiological disease on imaging it is 289 
difficult to determine what proportion of this difference in QoL is directly attributable to P. 290 
aeruginosa. All of the analyses described herein are subjective to the same limitation, that P. 291 
aeruginosa may be to some extent a reflection of the severity of underlying disease rather than a 292 
directly cause of disease progression. The only way to conclusively prove or quantify the 293 
independent effects of P. aeruginosa on outcome is likely to be through a large randomised 294 
controlled trial of P. aeruginosa eradication treatment which has been highlighted as a clear priority 295 
for the bronchiectasis research community.(42) Demonstrating that mortality, hospital admissions, 296 
exacerbations, QoL and lung function are improved or cease to decline after successful eradication 297 
would clearly demonstrate the independent impact of P. aeruginosa. A strength of our analysis is 298 
that it provides the most precise estimates to date of P. aeruginosa prevalence and impact in order 299 
to power future trials. 300 
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Current national guidelines for bronchiectasis recommend eradication treatment for new isolation of 301 
P. aeruginosa, largely based on recommendations for CF.(8,14,43) Data in bronchiectasis is limited to 302 
date and further research is greatly needed.  303 
Important gaps in the literature identified through this analysis include an absence of data available 304 
outside Europe and Australasia with a large proportion of included data from the UK; broad, 305 
representative registries for patients with bronchiectasis are needed internationally. Few studies 306 
examining lung function decline were identified, and those that were found were small with 307 
inconsistent results. We would recommend further large studies of lung function decline in 308 
bronchiectasis. There is a lack of data describing the impact of organisms other than P. aeruginosa in 309 
bronchiectasis and in particular comparing the outcomes of P. aeruginosa colonised patients with 310 
those colonised with the most common bronchiectasis pathogens such as H. influenzae or Moraxella 311 
catarrhalis. Such data would be valuable as recent reports suggest that these patients do have a 312 
worse outcome compared to non-colonised patients, but to a lesser extent than P. aeruginosa.(24) 313 
For example in the Bronchiectasis Severity Index, 3 points are awarded to patients with P. 314 
aeruginosa colonisation and 1 point to patients colonised with other pathogens.(24) For this meta-315 
analysis, we were able to identify 8 cohorts with data to compare outcomes between P. aeruginosa 316 
and H. Influenzae colonised patients and these confirmed the significantly worse clinical outcomes 317 
associated with P. aeruginosa.  318 
There is a need from both a clinical and research perspective to define chronic bacterial colonisation 319 
in bronchiectasis as this analysis identified 8 different methods of defining P. aeruginosa 320 
colonisation in bronchiectasis studies. The most frequently used definition was 2 or more positive 321 
cultures at least 3 months apart in 12 months. This should be standardised across studies to increase 322 
our ability to generalise results between studies and healthcare systems. Our data were almost 323 
entirely based on traditional bacterial culture and recent studies have increasingly used quantitative 324 
PCR or characterisation of the microbiome through sequencing of the 16s ribosomal RNA subunit to 325 
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determine bacterial colonisation status.(6,36,44) This method is significantly more sensitive for the 326 
detection of P. aeruginosa with Rogers et al. demonstrating very poor correlation between culture 327 
and PCR for P. aeruginosa detection: 91/107 patients in this study were positive for P. aeruginosa 328 
versus 31/107 by culture.(6) For this reason, further studies of the role of PCR in P. aeruginosa 329 
detection and to confirm eradication, would be beneficial.  330 
The word colonisation in this context is perhaps misleading. Colonisation implies a benign state 331 
defined by absence of tissue invasion or tissue damage. The term ‘chronic infection’ may be more 332 
appropriate given the clearly established association between the presence of bacteria and airway 333 
inflammation and the worse clinical outcomes observed in the presence of P. aeruginosa.  334 
 335 
In summary, P. aeruginosa colonisation is associated with increased mortality, hospital admissions 336 
and exacerbations, and is associated with worse QoL. As such, new Isolation of P. aeruginosa should 337 
be considered a highly significant clinical event and followed up with repeated cultures and attempts 338 
to eradicate in line with guideline recommendations. 339 
  340 
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Figure 1. Flow chart illustrating the process and results of the literature review. Abbreviations: QoL= 457 
quality of life; FEV1= forced expiratory volume in 1 second.  458 
 459 
Figure 2. Association between P. aeruginosa colonisation and mortality in bronchiectasis. 460 
Abbreviations: OR= odds ratio, M-H= Maentel-Haentzel, IV= inverse variance, CI= confidence 461 
interval,  462 
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Figure 3. Association between P. aeruginosa colonisation and hospital admissions in bronchiectasis. 465 
Abbreviations: OR= odds ratio, M-H= Maentel-Haentzel, IV= inverse variance, CI= confidence interval 466 
 467 
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Figure 4. Exacerbation frequency comparing patients with and without P. aeruginosa colonisation. 469 
Abbreviations: OR= odds ratio, M-H= Maentel-Haentzel, IV= inverse variance, CI= confidence interval 470 
 471 
Figure 5. FEV1 % predicted compared between patients with P. aeruginosa colonisation and patients 472 
without P. aeruginosa colonisation. Abbreviations: OR= odds ratio, M-H= Maentel-Haentzel, IV= 473 
inverse variance, CI= confidence interval 474 
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